Lowering LDL-C: The Role of Emerging CETP Inhibitors in Reducing Cardiovascular Risk
Released On
June 27, 2025
Expires On
June 26, 2026
Media Type
Internet
Completion Time
75 minutes
Specialty
Cardiology, Endocrinology, Geriatric Medicine, Pharmacy, Primary Care
Topics
Acute Coronary Syndrome, Acute Heart Failure, Acute Myocardial Infarction, Cardiovascular Disease, Geriatric Medicine, Heart, Heart Disease, Pharmacology
This continuing education activity is provided by
Educational Partner:
This activity is supported by an educational grant from NewAmsterdam Pharma B.V.
Credit Available
- Physicians — maximum of 1.25 AMA PRA Category 1 Credits™
- Pharmacists — 1.25 Contact Hours
- Nurses — 1.25 Nursing Contact Hours
All other healthcare professionals completing this course will be issued a statement of participation.
Target Audience
The intended audience for this activity includes cardiologists, endocrinologists, internal medicine physicians, pharmacists, and nurses involved in the management of patients with dyslipidemia and cardiovascular risk factors.
Program Overview
Despite updated treatment guidelines, a prevalent gap exists between recommended low-density lipoprotein cholesterol (LDL-C) goals and target attainment among patients with high-risk atherosclerotic cardiovascular disease (ASCVD). The current standard of care for these patients includes statins and ezetimibe for LDL-C reduction, with the addition of proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibiting monoclonal antibodies in higher risk patients. Genetic and pharmacokinetic evidence supports the utility of cholesterol ester transfer protein (CETP) inhibition for reducing both LDL-C and cardiovascular (CV) risk; however, initial clinical trials produced disappointing CV outcomes. In contrast, the CETP inhibitor, obicetrapib, has shown encouraging potential as a targeted treatment for dyslipidemia, with clinical study results demonstrating significant reductions in LDL-C and apolipoprotein B. In this CE activity, experts in the field review the data gaps in the attainment of LDL-C targets and the challenges associated with the management of ASCVD; outline the mechanisms by which CETP inhibitors reduce CV risk; and report the latest evidence on the safety and efficacy of novel CETP inhibitors. The Rapid-Fire Roundtable component of this activity engages the audience and faculty members in robust discussion on the renewed interest in CETP inhibition for dyslipidemia and CV risk reduction.
Learning Objectives
Upon successful completion of this activity, participants should be better able to:
- Review the need for additional nonstatin therapies that can lower LDL-C and reduce CV risk.
- Outline the mechanisms by which CETP inhibitors reduce CV risk.
- Assess the latest evidence on the safety and efficacy of emerging CETP inhibitors.
- Discuss strategies to improve the knowledge, skills, or performance of the healthcare team.
Faculty
Erin D. Michos, MD, MHS, FAHA, FACC, FASE, FASPC (Activity Chair)
Professor of Medicine
Director of Women’s Cardiovascular Health
Associate Director of Preventive Cardiology
Ciccarone Center for the Prevention of Cardiovascular Disease
Johns Hopkins University School of Medicine
Co-Editor in Chief,
The American Journal of Preventive Cardiology
Baltimore, MD
Christie M. Ballantyne, MD, FNLA, FACP, FACC
Chief, Section of Cardiovascular Research
Director, Center for Cardiometabolic Disease Prevention
Professor of Medicine, Molecular and Human Genetics, and Integrative Physiology
Baylor College of Medicine
President of the National Lipid Association
Houston, TX
Heather M. Johnson, MD, MS, MMM, FAHA, FACC, FASPC
Director of Preventive Cardiology for Women’s Services
Christine E. Lynn Women’s Health & Wellness Institute
Baptist Health South Florida – North Medical Group
Clinical Affiliate Associate Professor, Florida Atlantic University
Boca Raton, FL
Kausik Ray, MBChB, MD, MPhil, FRCP, FACC, FESC, FAHA
Professor of Public Health at the School of Public Health
Imperial College London Consultant Cardiologist
London, United Kingdom
Accreditation Statement
Credit Designation
Vindico Medical Education designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Participants who opt in by providing their ABIM ID and DOB (MM/DD) will earn MOC points equivalent to the amount of CME credits claimed for the activity.
Vindico Medical Education designates this activity for 1.25 nursing contact hours. Nurses should claim only the credit commensurate with the extent of their participation in the activity.
This program is acceptable for 1.25 contact hours of ACPE Continuing Education Credit. The ACPE Universal Program Number is JA0006104-9999-25-012-H01-P, effective 6/27/2025. This is a knowledge-based activity, and there is no fee to attend.
*IMPORTANT* Pharmacists MUST request credit within 60 days of activity completion. Upon receipt of the completed activity evaluation form, transcript information will be available at http://www.mycpemonitor.net within 4 weeks.
This enduring material is approved for 1 year from the date of original release, June 27, 2025, to June 26, 2026.
Disclosures of Conflicts Of Interest
Vindico Medical Education and National Lipid Association adhere to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a continuing education activity, including faculty, planners, reviewers, or others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Relationship information is accurate at the time of content development.
Erin D. Michos, MD (Activity Chair)
- Consultant: Amgen, Arrowhead, AstraZeneca, Bayer, Boehringer Ingelheim, Esperion, Ionis, Lilly, Merck, New Amsterdam, Novartis, Novo Nordisk
Christie M. Ballantyne, MD (Faculty)
- Consultant: 89Bio, Abbott Diagnostics, Amarin, Amgen, Arrowhead, AstraZeneca, Denka Seiken, Esperion, Genentech, Illumina, Ionis, Lilly, Merck, NewAmsterdam, Novartis, Novo Nordisk, Roche
Heather M. Johnson, MD (Faculty)
- Consultant: Amgen, Esperion, Novartis
- Speaker Contracted by Ineligible Company: Esperion
Kausik Ray, MBChB, MD (Faculty)
- Consultant: Abbott, Amarin, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, CRISPR, CSL Behring, EmendoBio, Esperion, Kowa, Lilly, NewAmsterdam Pharma, Novartis, Novo Nordisk, Pfizer, Regeneron, Resverlogix, Sanofi, Scribe Therapeutics, Silence Therapeutics, VAXXINITY, Viatris
- Speaker Contracted by Ineligible Company: Amarin, Amgen AstraZeneca, Boehringer Ingelheim, Daiichi Sankyo, Kyrka, Novartis, Novo Nordisk, Viatris
- Independent Research Contractor (paid to institution) : Amgen, Daiichi Sankyo, MSD, Pfizer, Regeneron, Ultragenyx
- Individual Stocks (publicly traded): NewAmsterdam Pharma, Pemi31 Therapeutics
Planners
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
No relevant financial relationships to disclose.
Jennifer Frederick, PharmD, BCPS
No relevant financial relationships to disclose.
Barbara A. Niedz, PhD, RN, CPHQ
No relevant financial relationships to disclose.
Staff
Vindico Medical Education and National Lipid Association Staff
No relevant financial relationships to disclose.
Signed disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance and National Lipid Association.
Instructions for Participation and Credit
There are no fees for participating and receiving CME credit for this enduring activity.
To participate in this activity, you must read the objectives, answer the polling and pretest questions, view the content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 3 of the 4 posttest questions correctly. If a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credits™ certificate, Contact Hour(s) certificate, or CPE Statement of Credit.
Course Viewing Requirements
Supported Browsers:
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above
Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above
Disclosure of Unlabeled Use
The audience is advised that this continuing education activity may contain references to unlabeled uses of FDA-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.
Disclaimer
Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2025 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any Vindico Medical Education continuing education activity does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the FDA. All readers and continuing education participants should verify all information before treating patients or utilizing any product.
Procedures for Reporting Copyright Infringement
If you suspect that any content in this activity violates your copyright, you can request the removal of such content or restrict access to it by contacting our designated copyright agent (as outlined below). In your email, kindly provide the following details:
- Specify the copyrighted work you believe has been infringed upon.
- Describe the work and, if possible, include the location (eg, URL) of an authorized version of the work.
- Share your name, address, telephone number, and, if available, your email address.
- Assert that you genuinely believe that the use of the materials in question is not authorized by the copyright owner, its agent, or the law.
- Confirm that the information you have provided is accurate and send an attestation, "under penalty of perjury," that you are either the copyright owner or have the authority to act on behalf of the copyright owner.
- Provide a signature or its electronic equivalent from the copyright holder or a representative authorized to act on their behalf.
Our agent for copyright issues relating to this web activity is as follows:
Vindico Medical Education, LLC
Attn: Faith Bantivoglio
6900 Grove Road, Building 300
Thorofare, NJ 08086
[email protected]
or call: 856-994-9400, ext. 614
Contact Information
For CME questions please contact: [email protected].